TY - JOUR
T1 - Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus
AU - Vincent, FB
AU - Kandane-Rathnayake, R
AU - Hoi, AY
AU - Slavin, L
AU - Godsell, JD
AU - Kitching, AR
AU - Harris, J
AU - Nelson, C. L.
AU - Jenkins, A. J.
AU - Chrysostomou, A.
AU - Hibbs, ML
AU - Kerr, PG
AU - Rischmueller, M.
AU - Mackay, F
AU - Morand, EF
PY - 2018/11/1
Y1 - 2018/11/1
N2 - INTRODUCTION: We examined the clinical relevance of urinary concentrations of B-cell-activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in systemic lupus erythematosus (SLE).METHODS: We quantified urinary BAFF (uBAFF) by enzyme-linked immunosorbent assay in 85 SLE, 28 primary Sjögren syndrome (pSS), 40 immunoglobulin A nephropathy (IgAN) patients and 36 healthy controls (HCs). Urinary APRIL (uAPRIL) and monocyte chemoattractant protein 1 (uMCP-1) were also quantified. Overall and renal SLE disease activity were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000.RESULTS: uBAFF was detected in 12% (10/85) of SLE patients, but was undetectable in HCs, IgAN and pSS patients. uBAFF was detectable in 28% (5/18) of SLE patients with active nephritis vs 5/67 (7%) of those without ( p = 0.03), and uBAFF was significantly higher in active renal patients ( p = 0.02) and more likely to be detected in patients with persistently active renal disease. In comparison, uAPRIL and uMCP-1 were detected in 32% (25/77) and 46% (22/48) of SLE patients, respectively. While no difference in proportion of samples with detectable uAPRIL was observed between SLE, HCs and IgAN patients, both uAPRIL and uMCP-1 were significantly detectable in higher proportions of patients with active renal disease.CONCLUSIONS: uBAFF was detectable in a small but a significant proportion of SLE patients but not in other groups tested, and was higher in SLE patients with active renal disease.
AB - INTRODUCTION: We examined the clinical relevance of urinary concentrations of B-cell-activating factor of the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) in systemic lupus erythematosus (SLE).METHODS: We quantified urinary BAFF (uBAFF) by enzyme-linked immunosorbent assay in 85 SLE, 28 primary Sjögren syndrome (pSS), 40 immunoglobulin A nephropathy (IgAN) patients and 36 healthy controls (HCs). Urinary APRIL (uAPRIL) and monocyte chemoattractant protein 1 (uMCP-1) were also quantified. Overall and renal SLE disease activity were assessed using the Systemic Lupus Erythematosus Disease Activity Index 2000.RESULTS: uBAFF was detected in 12% (10/85) of SLE patients, but was undetectable in HCs, IgAN and pSS patients. uBAFF was detectable in 28% (5/18) of SLE patients with active nephritis vs 5/67 (7%) of those without ( p = 0.03), and uBAFF was significantly higher in active renal patients ( p = 0.02) and more likely to be detected in patients with persistently active renal disease. In comparison, uAPRIL and uMCP-1 were detected in 32% (25/77) and 46% (22/48) of SLE patients, respectively. While no difference in proportion of samples with detectable uAPRIL was observed between SLE, HCs and IgAN patients, both uAPRIL and uMCP-1 were significantly detectable in higher proportions of patients with active renal disease.CONCLUSIONS: uBAFF was detectable in a small but a significant proportion of SLE patients but not in other groups tested, and was higher in SLE patients with active renal disease.
KW - A proliferation-inducing ligand (APRIL)
KW - B-cell–activating factor from the tumour necrosis factor family (BAFF)
KW - biomarker
KW - lupus nephritis (LN)
KW - monocyte chemoattractant protein 1 (MCP-1)
KW - systemic lupus erythematosus (SLE)
UR - http://www.scopus.com/inward/record.url?scp=85055660461&partnerID=8YFLogxK
U2 - 10.1177/0961203318804885
DO - 10.1177/0961203318804885
M3 - Article
C2 - 30301439
AN - SCOPUS:85055660461
SN - 0961-2033
VL - 27
SP - 2029
EP - 2040
JO - Lupus
JF - Lupus
IS - 13
ER -